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Abstract 
Fibroblast growth factor (FGF) 21 belongs to the FGF superfamily that is involved in cell 
proliferation and differentiation, neural development, angiogenesis and metabolism.  FGF21 
requires β-Klotho as a co-receptor. Tissues involved in metabolism such as the liver, adipose 
tissues, skeletal muscle and pancreas express FGF21. Starvation increases hepatic expression 
of FGF21, which then acts centrally to increase hepatic gluconeogenesis. FGF21 also 
increases fatty acid oxidation. This may be relevant in cold exposure, when expression of 
FGF21 is induced. Chronic treatment with recombinant FGF21 reduces serum and hepatic 
triglyceride levels, and ameliorates fatty liver in obese mice, through the suppression of the 
lipogenic gene, Srebp-1. FGF21 reduces hepatic cholesterol production by inhibiting Srebp-2, 
a transactivator of proprotein convertase subtilisin/kexin type 9 (PCSK9). LY2045319, an 
FGF21 analog, reduces LDL-C and triglycerides, and increases HDL-C in obese human 
subjects with type 2 diabetes. FGF21 does not seem to lower blood pressure acutely. In rats 
fed with high-fructose water to induce mild hypertension, 4-week treatment with recombinant 
FGF21 led to normalization of systolic blood pressure and improved serum lipid profile. FGF 
receptors and β-Klotho are expressed on the nucleus tractus solitarii and nodose ganglion in 
the baroreflex afferent pathway. Moreover, FGF21 acts on the hypothalamus to release 
corticosterone and induces in adipocytes the production of adiponectin, an adipokine with 
anti-hypertensive activities. Therefore, FGF21 may decrease blood pressure indirectly, 
through its actions in the liver, brain and adipose tissues.  
  
Introduction 
Fibroblast growth factor (FGF) 21 belongs to the FGF superfamily that comprises 22 
members with a wide range of biological functions, including cell proliferation and 
differentiation, neural development, angiogenesis and metabolism [1-3]. While the classic 
FGFs bind to the cell-surface tyrosine kinase FGF receptors (FGFRs) via a high-affinity 
interaction with heparin sulfate glycosaminoglycans (HSGAGs) and act in a paracrine or 
autocrine manner, FGF21 lacks the conventional heparin-binding domain. This means that it 
can escape from tissues rich in HSGAGs and be secreted into the bloodstream to act as an 
endocrine hormone [4, 5]. FGF21 requires a single-pass transmembrane glycoprotein β-
Klotho as a co-receptor for binding and activation of FGFRs [6, 7]. Unlike the ubiquitous 
expression of FGFRs, the expression of β-Klotho is limited to a number of metabolically 
active tissues including liver, adipose tissues, brain and pancreas, and therefore determines 
the tissue selectivity of FGF21’s actions [8]. Although the highest expression of FGF21 was 
initially identified in liver and thymus [9], later studies reported its expression in other 
metabolic tissues such as adipose tissues [10, 11], skeletal muscle [12] and pancreas [13, 14]. 
Physiologically, expression of FGF21 is induced in these tissues by various nutritional and 
environmental stressors to mediate adaptive metabolic responses [15]. Hepatic expression of 
FGF21 is dramatically induced by starvation through the activation of peroxisome 
proliferator-activated receptor α (PPARα) which results in an increase in circulating FGF21. 
Elevated serum FGF21 crosses the blood-brain barrier and acts directly on the hypothalamic 
neurons to stimulate the expression of corticotropin-releasing hormone, thereby induces the 
release of corticosterone via the hypothalamic-pituitary-adrenal (HPA) axis to increase 
hepatic gluconeogenesis and maintain glucose homeostasis during prolonged fasting [16]. In 
addition, fasting-induced hepatic FGF21 increases fatty acid oxidation and ketogenesis 
through the induction of peroxisome proliferator-activated receptor γ coactivator protein-1α 
(PGC-1α) to provide the brain with ketone bodies as energy fuels during severe carbohydrate 
deficit [17]. In contrast to the induction of hepatic FGF21 by starvation and stimulation with 
PPARα agonists, the expression of FGF21 in white adipose tissue (WAT) is increased by 
feeding and stimulation with the peroxisome proliferator-activated receptor γ (PPARγ) 
agonist, rosiglitazone [11]. Unlike fasting-induced hepatic FGF21 that is released into the 
circulation and acts as an endocrine hormone, feeding-induced expression of FGF21 in WAT 
does not lead to an elevation in serum FGF21, but acts on WAT in a feed-forward loop to 
mediate the insulin-sensitizing effects of PPARγ in an autocrine manner [11]. On the other 
hand, FGF21 is induced by cold exposure or β3-adrenergic receptor agonists through the 
cAMP-protein kinase A-p38 MAPK signaling pathway in both white and brown adipose 
tissues to regulate browning and adaptive thermogenic responses in mice [10, 18]. In addition 
to the cold-induced FGF21 expression in adipose tissues, mitochondrial dysfunction also 
leads to the release of FGF21 from skeletal muscle which in turn activates browning of WAT 
to counteract diet-induced obesity and insulin resistance in mice [12].  
Pharmacologically, FGF21 has been demonstrated to have pleiotropic effects against 
obesity and its related metabolic diseases [15]. The first evidence was provided by a high-
throughput screening for insulin-like agents that are capable of inducing glucose uptake in 
adipocytes [19]. Subsequent in vivo studies demonstrated that therapeutic administration of 
recombinant FGF21 protein or transgenic over-expression of FGF21 in both obese mice and 
diabetic monkeys leads to multiple beneficial effects, including reduction in body weight, 
substantial alleviation of hyperglycemia and hyperlipidemia, and protection against fatty liver 
diseases and insulin resistance, at least partially by improving β-cell survival and function or 
by increasing energy expenditure [17, 19-23]. Notably, later studies from two independent 
groups demonstrated that pharmacological effects of FGF21 on body weight reduction and 
glucose homeostasis persist in uncoupling protein 1 (UCP1)-null mice, reflecting discrete 
effects of FGF21 on metabolic regulation and UCP1-dependent thermogenesis [24, 25]. 
However, these findings do not rule out the possible role of UCP1-independent 
thermogenesis in conferring the beneficial effects of FGF21 on maintenance of energy 
homeostasis.  
Apart from extensive investigations on the metabolic activities of FGF21, recent 
studies show protective roles of FGF21 in the cardiovascular system [15]. Positive 
associations between serum levels of FGF21 and cardiovascular events in human, including 
coronary heart disease [26] and various types of atherosclerosis [27-29] were reported in 
several studies. In line with these clinical findings, serum FGF21 level is also increased with 
aging in apolipoprotein E-deficient (apoE-/-) mice with spontaneous development of 
atherosclerosis [30]. It protects apoE-/- mice against atherosclerosis possibly via alleviation of 
vascular inflammation and hypercholesterolemia by inducing adiponectin and suppressing 
sterol regulatory element-binding protein (Srebp)-2, respectively [30]. Emerging studies 
started to focus on the association of FGF21 with hypertension. Surprisingly, whether there is 
any causal relationship between FGF21 and blood pressure has not been well investigated. 
This review summarizes recent clinical and animal studies in this field, and raises some 
plausible possibilities for the potential roles of FGF21 in hypertension. 
 
Hypertension and Dyslipidemia 
Hypertension, or raised blood pressure, is highly prevalent globally, affecting about 
one-third of adults [31, 32]. Although the proportion of uncontrolled hypertension has 
slightly dropped since 1980, the overall prevalence of hypertension increased from 600 
million in 1980 to almost 1 billion in 2008 due to the growth of world population and ageing 
[33]. Hypertension is a major risk factor for numerous comorbidities such as coronary heart 
disease, ischemic and hemorrhagic stroke, heart failure, peripheral vascular disease and 
chronic kidney disease, and is therefore associated with at least 7.6 million deaths per year 
worldwide [34, 35]. Although the exact causes of hypertension are obscure, evidence is 
accumulating that obesity and dyslipidemia are key risk factors for the development of 
hypertension [36]. In an early national survey of adults in the United States, a strong 
association of body mass index (BMI) with the incidence of hypertension was found [37]. In 
a prospective 14-year follow-up study that included over 3000 men, those in the highest 
quintile of total cholesterol (TC) and non-HDL-C had increased risks of developing incident 
hypertension by 23% and 39%, respectively; whereas, men in the highest quintile of HDL-C 
had 32% reduced risk of hypertension than those in the lowest quintile [38]. It was further 
suggested that the association between blood pressure and serum cholesterol was independent 
of other variables such as body weight, blood glucose and insulin levels [39]. The 
relationship between dyslipidemia and hypertension is also evident by the term dyslipidemic 
hypertension (DH), which was first described by Williams et al. that a higher-than-expected 
occurrence of extreme lipid values was observed among middle-aged men with familial 
hypertension [40]. In line with these findings, statins have been suggested to have an 
amelioratory effect on blood pressure in hypertensive patients with hypercholesterolemia [41, 
42]. 
Emerging epidemiological evidences suggest a clinical association between serum 
FGF21 levels and hypertension in different ethnic groups. It was first reported by Semba et al. 
that elevated serum level of FGF21 was associated with hypertension after adjustments with 
multiple explanatory variables in a prospective open cohort study of community-dwelling 
adults in the United States [43]. The association of serum FGF21 with blood pressure has 
been observed in other populations, including Chinese [28, 44], Japanese [45, 46]. This is in 
line with an earlier study demonstrating an association of elevated serum FGF21 with 
increased arterial stiffness, which has been shown to have a bidirectional association with 
hypertension [47], in obese women [48]. Although there is a clear correlation between serum 
FGF21 and blood pressure, efforts to determine if this is a causal relationship remain ongoing. 
 
Potential Roles of FGF21 in Hypertension through Lipid Regulation 
Therapeutic administration of FGF21 has been shown to alleviate dyslipidemia in 
obese and diabetic mice, monkeys and human patients. Chronic treatment with recombinant 
FGF21 reduces serum and hepatic triglyceride levels and ameliorates fatty liver in diet-
induced obese mice potentially via the suppression of lipogenic gene, Srebp-1 [20]. In 
addition to the regulation of Srebp-1, the study showed an inhibitory effect of FGF21 on 
Srebp-2, which is a master regulator of cholesterol biosynthesis by preferentially activating 
the transcription of key cholesterologenic genes in the liver [30] (Figure 1). FGF21 
deficiency leads to increased hepatic cholesterol biosynthesis in liver and exacerbated 
hypercholesterolemia with a shift of apolipoprotein profiles from HDL to LDL in apoE-/- 
mice, suggesting FGF21 as a physiological suppressor of hepatic cholesterol production [49]. 
Intriguingly, SREBP-2 is the most important and well-established transactivator of proprotein 
convertase subtilisin/kexin type 9 (PCSK9) [50], which binds and targets low-density-
lipoprotein (LDL) receptor (LDLR) to lysosome degradation and in turn affects LDL 
cholesterol (LDL-C) catabolism. Reduced serum LDL-C levels are found in mice with gene 
inactivation of Pcsk9 [51]. Autosomal dominant hypercholesterolemia is found in patients 
with Pcsk9 gain-of-function mutations, and can be reversed by treatment with a PCSK9 
monoclonal antibody [52]. Based on these studies, FGF21 is proposed to lower serum LDL-C 
levels potentially via the suppression of the Srebp-2 and Pcsk9 [53]. Studies on the regulation 
of lipid metabolism by FGF21 have been extended to non-human primates. When treated 
with recombinant FGF21 or engineered FGF21 variants, reduction in serum triglycerides, 
very low-density-lipoprotein cholesterol (VLDL-C), LDL-C, with an increase in high-
density-lipoprotein cholesterol (HDL-C) was clearly observed in obese/diabetic monkeys [23, 
54, 55]. 
Another important mechanism whereby FGF21 may influence blood pressure is 
through its induction of the production of adiponectin in adipocytes. Adiponectin stimulates 
endothelial nitric oxide synthase activity and increases the production of nitric oxide (Figure 
1). In man, blood adiponectin level correlates with endothelial function [56] and blood 
pressure [57].  
In Sprague-Dawley (SD) rats fed high-fructose water to induce mild hypertension, 4-
week treatment with recombinant FGF21 led to normalization of systolic blood pressure in 
parallel with improved serum lipid profiles, including decreased total cholesterol and 
triglyceride levels in the hypertensive rats [58]. This suggests a functional role of FGF21 in 
ameliorating high-fructose induced hypertension possibly through its lipid lowering effects.  
 
FGF21 and Neural Control of Blood Pressure 
Despite the well-established roles of FGF21 in the regulation of lipid metabolism in 
both liver and adipose tissues, more recent studies have shown that FGF21 travels across the 
blood-brain barrier and acts centrally to regulate various functions such as female 
reproduction [59], glucose metabolism [16], circadian behavior [60] and energy expenditure 
[61] through its actions on hypothalamus. Importantly, one recent study has demonstrated the 
expression of all subtypes of FGFRs (FGFR1-4) and β-Klotho on the nucleus tractus solitarii 
(NTS) and nodose ganglion (NG) in the baroreflex afferent pathway, which plays a key role 
in the modulation of blood pressure [62]. Chronic intraperitoneal infusion of recombinant 
FGF21 exerted beneficial effects on systolic blood pressure and baroreflex sensitivity in the 
high fructose-drinking rats. The up-regulation in baroreflex sensitivity was associated with 
activation of the Akt-eNOS-NO signaling pathway in NTS and NG induced by acute 
intravenous administration of FGF21, although acute FGF21 treatment did not lead to any 
significant change in blood pressure [62]. This may imply that the effect of FGF21 on the 
regulation of blood pressure may be cumulative rather than immediate. 
In addition to the action on the baroreflex sensitivity, the aforementioned study 
demonstrated that FGF21 directly acts on the hypothalamic neurons and activates the 
hypothalamic-pituitary-adrenal (HPA) axis to release corticosterone [16] (Figure 1). Notably, 
corticosterone has been widely reported to be involved in the suppression of hypertension [63, 
64]. Therefore, FGF21 may also lower blood pressure through the regulation of 
corticosterone. 
 
FGF21 in Clinical Trials 
Recently, the pharmacological effects of FGF21 in human have been tested in two 
independent clinical trials. LY2045319, an FGF21 analog has been used to treat obese human 
subjects with type 2 diabetes (T2D). Patients treated with the FGF21 analog have shown 
improved lipid profiles, including reduced LDL-C and triglycerides, and increased HDL-C 
when compared to patients receiving placebo [65]. Although no significant change in blood 
pressure was observed in obese patients treated with LY2405319, one subject was reported to 
develop hypotension and discontinued from the study, which may imply a role of the FGF21 
analog in the reduction of blood pressure in human [65]. However, as only 38 patients were 
included in the above study, the effects of FGF21 on the regulation of blood pressure in 
humans is worthy of further investigations.  More recently, another long-acting FGF21 
molecule, PF-05231023, has been tested in patients with T2D and also showed efficacy in 
body weight reduction and improvement in circulating lipid profiles [66]. There is no 
evidence so far that FGF21 or its analogue lowers blood pressure in humans, but arguably, 
there have not been studies designed to measure small changes in blood pressure in both 
normotensive and hypertensive persons. Moreover, even the blood pressure-lowering effect 
of established antihypertensive drugs is not always immediate, so clinical studies of 
antihypertensive effects should be at least 6-8 weeks in duration.   It is currently unclear 
whether elevated serum FGF21 levels are due to the compensatory responses or the presence 
of FGF21 resistance, a phenomenon observed in many previous studies [67]. 
 
Conclusions 
FGF21 is known to have pleiotropic effects on lipid and glucose metabolism. 
Emerging evidence from both clinical and rodent studies suggested potential roles of FGF21 
in the pathophysiology of hypertension. Caution is needed in extrapolating experimental 
findings from animal models to man. Further studies are therefore needed to clarify the role 
of FGF21 in hypertension and to explore the use of FGF21 as a possible therapeutic target. At 
least, serum FGF21 is a biomarker of hypertension. Moreover, FGF21 and its analogues 
appear to have beneficial effects on lipid and glucose metabolism in man. The idea of one 
drug that can treat obesity, diabetes, dyslipidemia and hypertension all at once might have 
seemed impossible a few years ago, but is now a tantalizing and exciting prospect. 
 
 Fig.1. Potential roles of fibroblast growth factor (FGF21) in the modulation of blood 
pressure via the crosstalk between liver, white adipose tissue, brain and blood vessels. 
HPA, hypothalamic-pituitary-adrenal; LDL-C, low-density-lipoprotein cholesterol; NG, 
nodose ganglion; NTS, nucleus tractus solitarii; Pcsk9, proprotein convertase subtilisin/kexin 
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